230 related articles for article (PubMed ID: 36070144)
21. Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling.
Herz HM; Morgan M; Gao X; Jackson J; Rickels R; Swanson SK; Florens L; Washburn MP; Eissenberg JC; Shilatifard A
Science; 2014 Aug; 345(6200):1065-70. PubMed ID: 25170156
[TBL] [Abstract][Full Text] [Related]
22. A lesson learned from the H3.3K27M mutation found in pediatric glioma: a new approach to the study of the function of histone modifications in vivo?
Chan KM; Han J; Fang D; Gan H; Zhang Z
Cell Cycle; 2013 Aug; 12(16):2546-52. PubMed ID: 23907119
[TBL] [Abstract][Full Text] [Related]
23. Histone H3K27 methylation modulates the dynamics of FANCD2 on chromatin to facilitate NHEJ and genome stability.
Zhang Y; Chang JF; Sun J; Chen L; Yang XM; Tang HY; Jing YY; Kang X; He ZM; Wu JY; Wei HM; Wang DL; Xu RG; Zhu RB; Shen Y; Zeng SY; Wang C; Liu KN; Zhang Y; Mao ZY; Jiang CZ; Sun FL
J Cell Sci; 2018 Jun; 131(12):. PubMed ID: 29760279
[TBL] [Abstract][Full Text] [Related]
24. Cancer-driving H3G34V/R/D mutations block H3K36 methylation and H3K36me3-MutSα interaction.
Fang J; Huang Y; Mao G; Yang S; Rennert G; Gu L; Li H; Li GM
Proc Natl Acad Sci U S A; 2018 Sep; 115(38):9598-9603. PubMed ID: 30181289
[TBL] [Abstract][Full Text] [Related]
25. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas.
Mohammad F; Weissmann S; Leblanc B; Pandey DP; Højfeldt JW; Comet I; Zheng C; Johansen JV; Rapin N; Porse BT; Tvardovskiy A; Jensen ON; Olaciregui NG; Lavarino C; Suñol M; de Torres C; Mora J; Carcaboso AM; Helin K
Nat Med; 2017 Apr; 23(4):483-492. PubMed ID: 28263309
[TBL] [Abstract][Full Text] [Related]
26. Integrated Metabolic and Epigenomic Reprograming by H3K27M Mutations in Diffuse Intrinsic Pontine Gliomas.
Chung C; Sweha SR; Pratt D; Tamrazi B; Panwalkar P; Banda A; Bayliss J; Hawes D; Yang F; Lee HJ; Shan M; Cieslik M; Qin T; Werner CK; Wahl DR; Lyssiotis CA; Bian Z; Shotwell JB; Yadav VN; Koschmann C; Chinnaiyan AM; Blüml S; Judkins AR; Venneti S
Cancer Cell; 2020 Sep; 38(3):334-349.e9. PubMed ID: 32795401
[TBL] [Abstract][Full Text] [Related]
27. Histone Variant and Cell Context Determine H3K27M Reprogramming of the Enhancer Landscape and Oncogenic State.
Nagaraja S; Quezada MA; Gillespie SM; Arzt M; Lennon JJ; Woo PJ; Hovestadt V; Kambhampati M; Filbin MG; Suva ML; Nazarian J; Monje M
Mol Cell; 2019 Dec; 76(6):965-980.e12. PubMed ID: 31588023
[TBL] [Abstract][Full Text] [Related]
28. Automethylation of PRC2 promotes H3K27 methylation and is impaired in H3K27M pediatric glioma.
Lee CH; Yu JR; Granat J; Saldaña-Meyer R; Andrade J; LeRoy G; Jin Y; Lund P; Stafford JM; Garcia BA; Ueberheide B; Reinberg D
Genes Dev; 2019 Oct; 33(19-20):1428-1440. PubMed ID: 31488577
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic programming of pediatric high-grade glioma: Pushing beyond proof of concept to clinical benefit.
Groves A; Cooney TM
Front Cell Dev Biol; 2022; 10():1089898. PubMed ID: 36589742
[TBL] [Abstract][Full Text] [Related]
30. Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas.
Bechet D; Gielen GG; Korshunov A; Pfister SM; Rousso C; Faury D; Fiset PO; Benlimane N; Lewis PW; Lu C; David Allis C; Kieran MW; Ligon KL; Pietsch T; Ellezam B; Albrecht S; Jabado N
Acta Neuropathol; 2014 Nov; 128(5):733-41. PubMed ID: 25200321
[TBL] [Abstract][Full Text] [Related]
31. H3.3K27M mutant proteins reprogram epigenome by sequestering the PRC2 complex to poised enhancers.
Fang D; Gan H; Cheng L; Lee JH; Zhou H; Sarkaria JN; Daniels DJ; Zhang Z
Elife; 2018 Jun; 7():. PubMed ID: 29932419
[TBL] [Abstract][Full Text] [Related]
32. Histone H3-wild type diffuse midline gliomas with H3K27me3 loss are a distinct entity with exclusive EGFR or ACVR1 mutation and differential methylation of homeobox genes.
Ajuyah P; Mayoh C; Lau LMS; Barahona P; Wong M; Chambers H; Valdes-Mora F; Senapati A; Gifford AJ; D'Arcy C; Hansford JR; Manoharan N; Nicholls W; Williams MM; Wood PJ; Cowley MJ; Tyrrell V; Haber M; Ekert PG; Ziegler DS; Khuong-Quang DA
Sci Rep; 2023 Mar; 13(1):3775. PubMed ID: 36882456
[TBL] [Abstract][Full Text] [Related]
33. H3-K27M-mutant nucleosomes interact with MLL1 to shape the glioma epigenetic landscape.
Furth N; Algranati D; Dassa B; Beresh O; Fedyuk V; Morris N; Kasper LH; Jones D; Monje M; Baker SJ; Shema E
Cell Rep; 2022 May; 39(7):110836. PubMed ID: 35584667
[TBL] [Abstract][Full Text] [Related]
34. Histone-Mutant Glioma: Molecular Mechanisms, Preclinical Models, and Implications for Therapy.
Graham MS; Mellinghoff IK
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33003625
[TBL] [Abstract][Full Text] [Related]
35. Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas.
Fontebasso AM; Schwartzentruber J; Khuong-Quang DA; Liu XY; Sturm D; Korshunov A; Jones DT; Witt H; Kool M; Albrecht S; Fleming A; Hadjadj D; Busche S; Lepage P; Montpetit A; Staffa A; Gerges N; Zakrzewska M; Zakrzewski K; Liberski PP; Hauser P; Garami M; Klekner A; Bognar L; Zadeh G; Faury D; Pfister SM; Jabado N; Majewski J
Acta Neuropathol; 2013 May; 125(5):659-69. PubMed ID: 23417712
[TBL] [Abstract][Full Text] [Related]
36. Immunostaining of Increased Expression of Enhancer of Zeste Homolog 2 (EZH2) in Diffuse Midline Glioma H3K27M-Mutant Patients with Poor Survival.
Karlowee V; Amatya VJ; Takayasu T; Takano M; Yonezawa U; Takeshima Y; Sugiyama K; Kurisu K; Yamasaki F
Pathobiology; 2019; 86(2-3):152-161. PubMed ID: 31096221
[TBL] [Abstract][Full Text] [Related]
37. The H3.3K27M oncohistone affects replication stress outcome and provokes genomic instability in pediatric glioma.
Bočkaj I; Martini TEI; de Camargo Magalhães ES; Bakker PL; Meeuwsen-de Boer TGJ; Armandari I; Meuleman SL; Mondria MT; Stok C; Kok YP; Bakker B; Wardenaar R; Seiler J; Broekhuis MJC; van den Bos H; Spierings DCJ; Ringnalda FCA; Clevers H; Schüller U; van Vugt MATM; Foijer F; Bruggeman SWM
PLoS Genet; 2021 Nov; 17(11):e1009868. PubMed ID: 34752469
[TBL] [Abstract][Full Text] [Related]
38. Histone H3K9 methyltransferase SETDB1 overexpression correlates with pediatric high-grade gliomas progression and prognosis.
Klonou A; Korkolopoulou P; Giannopoulou AI; Kanakoglou DS; Pampalou A; Gargalionis AN; Sarantis P; Mitsios A; Sgouros S; Papavassiliou AG; Piperi C
J Mol Med (Berl); 2023 Apr; 101(4):387-401. PubMed ID: 36811655
[TBL] [Abstract][Full Text] [Related]
39. Epigenetically defined therapeutic targeting in H3.3G34R/V high-grade gliomas.
Sweha SR; Chung C; Natarajan SK; Panwalkar P; Pun M; Ghali A; Bayliss J; Pratt D; Shankar A; Ravikumar V; Rao A; Cieslik M; Wilder-Romans K; Scott AJ; Wahl DR; Jessa S; Kleinman CL; Jabado N; Mackay A; Jones C; Martinez D; Santi M; Judkins AR; Yadav VN; Qin T; Phoenix TN; Koschmann CJ; Baker SJ; Chinnaiyan AM; Venneti S
Sci Transl Med; 2021 Oct; 13(615):eabf7860. PubMed ID: 34644147
[TBL] [Abstract][Full Text] [Related]
40. Pediatric glioma histone H3.3 K27M/G34R mutations drive abnormalities in PML nuclear bodies.
Voon HPJ; Hii L; Garvie A; Udugama M; Krug B; Russo C; Chüeh AC; Daly RJ; Morey A; Bell TDM; Turner SJ; Rosenbluh J; Daniel P; Firestein R; Mann JR; Collas P; Jabado N; Wong LH
Genome Biol; 2023 Dec; 24(1):284. PubMed ID: 38066546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
